Global Generic and Biosimilar Pharmaceuticals 麻豆原创 Research Report 2024

Publication ID:

PB506247493

Publication Date:

June 7, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global Generic and Biosimilar Pharmaceuticals market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Generic and Biosimilar Pharmaceuticals, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Generic and Biosimilar Pharmaceuticals.
Report Scope
The Generic and Biosimilar Pharmaceuticals market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Generic and Biosimilar Pharmaceuticals market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Generic and Biosimilar Pharmaceuticals companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
Segment by Type
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Other
Segment by Application
Tumor
Diabetes
Cardiovascular
Hemophilia
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Generic and Biosimilar Pharmaceuticals companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Generic and Biosimilar Pharmaceuticals 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Monoclonal Antibodies
1.2.3 Interferon
1.2.4 Erythropoietin
1.2.5 Insulin
1.2.6 Vaccines
1.2.7 Other
1.3 麻豆原创 by Application
1.3.1 Global Generic and Biosimilar Pharmaceuticals 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Tumor
1.3.3 Diabetes
1.3.4 Cardiovascular
1.3.5 Hemophilia
1.3.6 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Generic and Biosimilar Pharmaceuticals 麻豆原创 Perspective (2019-2030)
2.2 Generic and Biosimilar Pharmaceuticals Growth Trends by Region
2.2.1 Global Generic and Biosimilar Pharmaceuticals 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Generic and Biosimilar Pharmaceuticals Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Generic and Biosimilar Pharmaceuticals Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Generic and Biosimilar Pharmaceuticals 麻豆原创 Dynamics
2.3.1 Generic and Biosimilar Pharmaceuticals Industry Trends
2.3.2 Generic and Biosimilar Pharmaceuticals 麻豆原创 Drivers
2.3.3 Generic and Biosimilar Pharmaceuticals 麻豆原创 Challenges
2.3.4 Generic and Biosimilar Pharmaceuticals 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Generic and Biosimilar Pharmaceuticals Players by Revenue
3.1.1 Global Top Generic and Biosimilar Pharmaceuticals Players by Revenue (2019-2024)
3.1.2 Global Generic and Biosimilar Pharmaceuticals Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Generic and Biosimilar Pharmaceuticals 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Generic and Biosimilar Pharmaceuticals Revenue
3.4 Global Generic and Biosimilar Pharmaceuticals 麻豆原创 Concentration Ratio
3.4.1 Global Generic and Biosimilar Pharmaceuticals 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Generic and Biosimilar Pharmaceuticals Revenue in 2023
3.5 Generic and Biosimilar Pharmaceuticals Key Players Head office and Area Served
3.6 Key Players Generic and Biosimilar Pharmaceuticals Product Solution and Service
3.7 Date of Enter into Generic and Biosimilar Pharmaceuticals 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Generic and Biosimilar Pharmaceuticals Breakdown Data by Type
4.1 Global Generic and Biosimilar Pharmaceuticals Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Generic and Biosimilar Pharmaceuticals Forecasted 麻豆原创 Size by Type (2025-2030)
5 Generic and Biosimilar Pharmaceuticals Breakdown Data by Application
5.1 Global Generic and Biosimilar Pharmaceuticals Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Generic and Biosimilar Pharmaceuticals Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Generic and Biosimilar Pharmaceuticals 麻豆原创 Size (2019-2030)
6.2 North America Generic and Biosimilar Pharmaceuticals 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Generic and Biosimilar Pharmaceuticals 麻豆原创 Size by Country (2019-2024)
6.4 North America Generic and Biosimilar Pharmaceuticals 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Generic and Biosimilar Pharmaceuticals 麻豆原创 Size (2019-2030)
7.2 Europe Generic and Biosimilar Pharmaceuticals 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Generic and Biosimilar Pharmaceuticals 麻豆原创 Size by Country (2019-2024)
7.4 Europe Generic and Biosimilar Pharmaceuticals 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Generic and Biosimilar Pharmaceuticals 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Generic and Biosimilar Pharmaceuticals 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Generic and Biosimilar Pharmaceuticals 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Generic and Biosimilar Pharmaceuticals 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Generic and Biosimilar Pharmaceuticals 麻豆原创 Size (2019-2030)
9.2 Latin America Generic and Biosimilar Pharmaceuticals 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Generic and Biosimilar Pharmaceuticals 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Generic and Biosimilar Pharmaceuticals 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Generic and Biosimilar Pharmaceuticals 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Generic and Biosimilar Pharmaceuticals 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Generic and Biosimilar Pharmaceuticals 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Generic and Biosimilar Pharmaceuticals 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Generic and Biosimilar Pharmaceuticals Introduction
11.1.4 Roche Revenue in Generic and Biosimilar Pharmaceuticals Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Generic and Biosimilar Pharmaceuticals Introduction
11.2.4 Amgen Revenue in Generic and Biosimilar Pharmaceuticals Business (2019-2024)
11.2.5 Amgen Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Detail
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Generic and Biosimilar Pharmaceuticals Introduction
11.3.4 AbbVie Revenue in Generic and Biosimilar Pharmaceuticals Business (2019-2024)
11.3.5 AbbVie Recent Development
11.4 Sanofi-Aventis
11.4.1 Sanofi-Aventis Company Detail
11.4.2 Sanofi-Aventis Business Overview
11.4.3 Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Introduction
11.4.4 Sanofi-Aventis Revenue in Generic and Biosimilar Pharmaceuticals Business (2019-2024)
11.4.5 Sanofi-Aventis Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Detail
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Generic and Biosimilar Pharmaceuticals Introduction
11.5.4 Johnson & Johnson Revenue in Generic and Biosimilar Pharmaceuticals Business (2019-2024)
11.5.5 Johnson & Johnson Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Generic and Biosimilar Pharmaceuticals Introduction
11.6.4 Pfizer Revenue in Generic and Biosimilar Pharmaceuticals Business (2019-2024)
11.6.5 Pfizer Recent Development
11.7 Novo Nordisk
11.7.1 Novo Nordisk Company Detail
11.7.2 Novo Nordisk Business Overview
11.7.3 Novo Nordisk Generic and Biosimilar Pharmaceuticals Introduction
11.7.4 Novo Nordisk Revenue in Generic and Biosimilar Pharmaceuticals Business (2019-2024)
11.7.5 Novo Nordisk Recent Development
11.8 Eli Lilly
11.8.1 Eli Lilly Company Detail
11.8.2 Eli Lilly Business Overview
11.8.3 Eli Lilly Generic and Biosimilar Pharmaceuticals Introduction
11.8.4 Eli Lilly Revenue in Generic and Biosimilar Pharmaceuticals Business (2019-2024)
11.8.5 Eli Lilly Recent Development
11.9 Novartis
11.9.1 Novartis Company Detail
11.9.2 Novartis Business Overview
11.9.3 Novartis Generic and Biosimilar Pharmaceuticals Introduction
11.9.4 Novartis Revenue in Generic and Biosimilar Pharmaceuticals Business (2019-2024)
11.9.5 Novartis Recent Development
11.10 Merck
11.10.1 Merck Company Detail
11.10.2 Merck Business Overview
11.10.3 Merck Generic and Biosimilar Pharmaceuticals Introduction
11.10.4 Merck Revenue in Generic and Biosimilar Pharmaceuticals Business (2019-2024)
11.10.5 Merck Recent Development
11.11 3sbio
11.11.1 3sbio Company Detail
11.11.2 3sbio Business Overview
11.11.3 3sbio Generic and Biosimilar Pharmaceuticals Introduction
11.11.4 3sbio Revenue in Generic and Biosimilar Pharmaceuticals Business (2019-2024)
11.11.5 3sbio Recent Development
11.12 Changchun High Tech
11.12.1 Changchun High Tech Company Detail
11.12.2 Changchun High Tech Business Overview
11.12.3 Changchun High Tech Generic and Biosimilar Pharmaceuticals Introduction
11.12.4 Changchun High Tech Revenue in Generic and Biosimilar Pharmaceuticals Business (2019-2024)
11.12.5 Changchun High Tech Recent Development
11.13 CP Guojian
11.13.1 CP Guojian Company Detail
11.13.2 CP Guojian Business Overview
11.13.3 CP Guojian Generic and Biosimilar Pharmaceuticals Introduction
11.13.4 CP Guojian Revenue in Generic and Biosimilar Pharmaceuticals Business (2019-2024)
11.13.5 CP Guojian Recent Development
11.14 Biotech
11.14.1 Biotech Company Detail
11.14.2 Biotech Business Overview
11.14.3 Biotech Generic and Biosimilar Pharmaceuticals Introduction
11.14.4 Biotech Revenue in Generic and Biosimilar Pharmaceuticals Business (2019-2024)
11.14.5 Biotech Recent Development
11.15 Gelgen
11.15.1 Gelgen Company Detail
11.15.2 Gelgen Business Overview
11.15.3 Gelgen Generic and Biosimilar Pharmaceuticals Introduction
11.15.4 Gelgen Revenue in Generic and Biosimilar Pharmaceuticals Business (2019-2024)
11.15.5 Gelgen Recent Development
11.16 Innovent
11.16.1 Innovent Company Detail
11.16.2 Innovent Business Overview
11.16.3 Innovent Generic and Biosimilar Pharmaceuticals Introduction
11.16.4 Innovent Revenue in Generic and Biosimilar Pharmaceuticals Business (2019-2024)
11.16.5 Innovent Recent Development
11.17 Dong Bao
11.17.1 Dong Bao Company Detail
11.17.2 Dong Bao Business Overview
11.17.3 Dong Bao Generic and Biosimilar Pharmaceuticals Introduction
11.17.4 Dong Bao Revenue in Generic and Biosimilar Pharmaceuticals Business (2019-2024)
11.17.5 Dong Bao Recent Development
11.18 Ganlee
11.18.1 Ganlee Company Detail
11.18.2 Ganlee Business Overview
11.18.3 Ganlee Generic and Biosimilar Pharmaceuticals Introduction
11.18.4 Ganlee Revenue in Generic and Biosimilar Pharmaceuticals Business (2019-2024)
11.18.5 Ganlee Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.